CSPC Pharma (01093) has announced the official initiation of the first clinical trial site in China for its Phase 1 study of the SYH2092 injection, targeting weight management in adults who are overweight or obese.

SYH2092 is an amylin receptor agonist developed by the group. By optimizing its agonistic activity, the product is designed to enhance therapeutic efficacy while maintaining a manageable tolerability profile in patients.

Furthermore, the compound features a fatty acid modification that extends its half-life in the body, potentially leading to sustained and durable weight-loss benefits for users.

Preclinical data suggests that, compared to several other amylin analogues currently undergoing clinical development, this candidate demonstrates superior target agonistic activity, more pronounced weight-reduction effects, and a longer-lasting maintenance of weight loss.

The group had previously received the Drug Clinical Trial Approval Notice from China's National Medical Products Administration in August 2026, and subsequently initiated the Phase 1 clinical trial for the product.

The newly launched Phase 1 study is intended to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of the product in healthy participants.

This therapeutic candidate holds the potential to deliver significant clinical benefits in weight management for obese patients, as well as to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).

Recruitment and screening of participants for the Phase 1 clinical trial are currently progressing in an active manner.